Date: 2015-07-16
Type of information: Series A financing round
Company: Immunocore (UK)
Investors: Woodford Investment Management (UK) Malin Corporation (UK) Eli Lilly (USA - IN) RTW Investments (USA - NY) new and existing investors
Amount: $320 million (£205 million)
Funding type: series A financing round
Planned used: The proceeds will enable Immunocore to further accelerate its pipeline of ImmTACs (Immune mobilising mTCR Against Cancer). ImmTACs are a new class of bispecific biologics which have the potential to treat a broad range of solid tumours either as monotherapies or in combination with other therapies to create best in class treatment regimes. In addition to delivering on its well-established partnerships, Immunocore will focus, in particular, on progressing its lead proprietary programme, IMCgp100, which produced positive Phase I/IIa trial data in April 2015 in patients with advanced
metastatic cutaneous and ocular melanoma.
Others: * On July 16, 2015, Immunocore, a world-leading biotechnology company developing novel T cell receptor (TCR) based biological drugs to treat cancer, viral infections and autoimmune disease, announced the completion of a $320
million (GBP £205 million) private financing round. The oversubscribed round includes new investors, Woodford Investment Management, Malin Corporation plc, Eli Lilly and Company and RTW Investments, as well as a number
of new and existing investors in Immunocore. Credit Suisse advised Immunocore on the financing round. Cooley LLP served as legal counsel to Immunocore.
Therapeutic area: Autoimmune diseases - Cancer - Oncology - Infectious diseases
